Correlations of survivin expression with clinicomorphological parameters and hormonal receptor status in breast ductal carcinoma

Neoplasma

Volumn 59, Issue 1, 2012, Pages 30-37

  Adamkov, M ^a   Kajo, K ^b   Vybohova, D ^a   Krajcovic, J ^a   Stuller, F ^a   Rajcani, J ^c  

^a Faculty of Natural Sciences   (Slovakia)

^b BB Biocyt   (Slovakia)

^c Alpha Medical as   (Slovakia)

Author keywords

Breast; Carcinoma; Clinicomorphological parameters; Survivin

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; SURVIVIN; BIRC5 PROTEIN, HUMAN; ESTROGEN; INHIBITOR OF APOPTOSIS PROTEIN; PROGESTERONE; TUMOR PROTEIN;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; PAGET NIPPLE DISEASE; PATHOLOGY; PROTEIN EXPRESSION; ADULT; AGED; BIOSYNTHESIS; BREAST TUMOR; CANCER INVASION; CANCER STAGING; CELL NUCLEUS; CHEMISTRY; CYTOPLASM; FEMALE; METASTASIS; MIDDLE AGED; MORTALITY; NEOPLASM; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL NUCLEUS; CYTOPLASM; ESTROGENS; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROGESTERONE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84863758293     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_004     Document Type: Article

References (47)

1. DEVERAUX QL, REED JC IAP family proteins-suppressors of apoptosis. Genes Dev 1999; 13: 239-252. http://dx.doi. org/10.1101/gad.13.3.239
2. AMIRI KI, RICHMOND A Role of nuclear factor-k B in melanoma. Cancer Metastasis Rev 2005; 24: 301-313. http://dx.doi.org/10.1007/s10555-005-1579-7
3. LI F Survivin study: what is the next wave? J Cell Physiol 2003; 197: 8-29. http://dx.doi.org/10.1002/jcp.10327
4. LI F Role of Survivin and its Splice Variants in Tumorigenesis. Br J Cancer 2005a; 92: 212-216.
5. LI F, BRATTAIN MG Role of the survivin gene in pathobiology. Am J Pathol 2006; 169: 1-11. http://dx.doi. org/10.2353/ajpath.2006.060121
6. MOON WS, TARNAWSKI AS Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth? Human Pathol 2003; 34: 1119-1126. http://dx.doi. org/10.1053/j.humpath.2003.07.016
7. VETTER CS, MÜLLER-BLECH K, SCHRAMA D, BRÖCKER EB, BECKER JC Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Arch Dermatol Res 2005; 297: 26-30. http://dx.doi.org/10.1007/s00403-005-0572-x
8. DING Y, PRIETO VG, ZHANG PS, ROSENTHAL S, SMITH KJ et al. Nuclear expression of the antiapoptoptic protein survivin in malignant melanoma. Cancer 2006; 106: 1123-1129. http://dx.doi.org/10.1002/cncr.21727
9. TANAKA K, IWAMOTO S, GON G, NOHARA T, IWAMOTO M et al.:Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-134.
10. CHU JS, SHEW JY, HUANG CS Immunohistochemical analysis of survivin expression in primary breast cancers. J Formos Med Assoc 2004; 103: 925-931.
11. KENNEDY SM, O'DRISCOLL L, PURCELL R, FITZ-SIMONS N, MCDERMOTT EW et al. Prognostic importance of survivin in breast cancer. Br J Cancer 2003; 88: 1077-1083. http://dx.doi.org/10.1038/sj.bjc.6600776
12. SPAN PN, SWEEP FCGJ, WIEGERINCK ETG, TJAN-HEIJNEN VCG, MANDERS P et al. Survivin is an independent prognostic marker for risk stratification of breas cancer patients. Clin Chem 2004; 50: 1986-1993. http://dx.doi.org/10.1373/clinchem.2004.039149
13. LI F, YANG J, RAMNATH N, JAVLE MM, TAN D Nuclear or cytoplasmic expression of survivin: What is the significance? Int J Cancer 2005b; 114: 509-512. http://dx.doi.org/10.1002/ijc.20768
14. DUFFY MJ, O'DONOVAN N, BRENNAN DJ, GALLAGHER WM, RYAN BM Survivin: A promising tumor biomarker. Cancer Lett 2007; 249: 49-60. http://dx.doi. org/10.1016/j.canlet.2006.12.020
15. PIRAS F, MURTAS D, MINERBA L, UGALDE J, FLORIS C et al. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology 2007; 50: 835-842. http://dx.doi. org/10.1111/j.1365-2559.2007.02695.x
16. ADAMKOV M, LAUKO L, RAJCANI J, BALENTOVA S, RYBAROVA S et al. Expression of antiapoptotic protein survivin in malignant melanoma. Biologia 2009a; 64: 840-844. http://dx.doi.org/10.2478/s11756-009-0134-3
17. ADAMKOV M, LAUKO L, BALENTOVA S, PEC J., PEC M et al. Expression pattern of anti-apoptotic protein survivin in dysplastic nevi. Neoplasma 2009; 56: 130-135. http://dx.doi. org/10.4149/neo_2009_02_130
18. JOHNSON ME, HOWERTH EW Survivin: A Bifunctional Inhibitor of Apoptosis Protein. Vet Pathol 2004; 41: 599-607. http://dx.doi.org/10.1354/vp.41-6-599
19. BRENNAN DJ, REXHEPAJ E, O'BRIEN SL, MCSHERRY E, O'CONNOR DP et al.: Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 2008; 14: 2681-2689. http://dx.doi.org/10.1158/1078-0432. CCR-07-1760
20. SONG KY, JUNG CHK, PARK WS, PARK CHH Expression of the antiapoptosis gene survivin predicts poor prognosis of stage III gastric adenocarcinoma. Jpn J Clin Oncol 2009; 39: 290-296. http://dx.doi.org/10.1093/jjco/hyp020
21. RYAN BM, KONECNY GE, KAHLERT S, WANG H-J, UNTCH M et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006; 17: 597-604. http://dx.doi.org/10.1093/annonc/mdj121
22. HINNIS AR, LUCKETT JC, WALKER RA Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 2007; 96: 639-645. http://dx.doi.org/10.1038/sj.bjc.6603616
23. ADAIR F, BERG J, JOUBERT L, ROBBINS GF Longterm follow-up of breast cancer patients: The 30-year report. Cancer 1974; 33: 1145-1150. http://dx.doi. org/10.1002/1097-0142(197404)33:4<1145::AIDCNCR2820330438> 3.0.CO;2-0
24. BLACK MM, BARCLAY THC, HANKEY BF Prognosis in breast cancer utilizing histologic characteristics of the primary tumor. Cancer 1975; 36: 2048-2055. http://dx.doi.org/10.1002/cncr.2820360919
25. SUTHERLAND CM, MATHER FJ Long-term survival and prognostic factors in patients with regional breast cancer. Cancer 1985; 55: 1389-1397. http://dx.doi. org/10.1002/1097-0142(19850315)55:6<1389::AIDCNCR2820550638> 3.0.CO;2-B
26. CARTER CL, ALLEN C, HENSON DE Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer cases. Cancer 1989; 63: 181-187. http://dx.doi.org/10.1002/1097-0142(19890101)63:1<181::AIDCNCR2820630129> 3.0.CO;2-H
27. DOUSSAL VLE, TUBIANA-HULIN M, FRIEDMAN S, HACENE K, SPYRATOS F et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989; 64: 1914-1921. http://dx.doi. org/10.1002/1097-0142(19891101)64:9<1914::AIDCNCR2820640926> 3.0.CO;2-G
28. TAVASSOLI FA Chapter 5. Benign lesions. In: Stamford, CT, editor. Pathology of the Breast. Second Edition. Hong Kong: Appleton & Lange, 1999:115-204.
29. DONEGAN WL, STINE SB, SAMTER TG Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer 1993; 72: 778-782. http://dx.doi.org/10.1002/1097-0142(19930801)72:3<778::AIDCNCR2820720324> 3.0.CO;2-J
30. SNEIGE N, LAGIOS M, SCHWARTING R, COLBURN W, ATKINSON E et al. Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. Hum Pathol 1999; 30: 257-262. http://dx.doi.org/10.1016/S0046-8177(99)90002-3
31. KAYASELCUK F, NURSAL TZ, POLAT A, NOYAN T, YILDIRIM S et al. Expression of survivin, bcl-2, p53 and bax in breast carcinoma and ductal intraepithelial neoplasia (DIN 1a). J Exp Clin Cancer Res 2004; 23: 105-111.
32. NASSAR A, LAWSON D, COTSONIS G, COHEN C Survivin and caspase-3 expression in breast cancer: correlation with prognosis parameters, proliferation, angiogenesis, and outcome. Appl Immunohistochem Mol Morphol 2008; 16: 113-120. http://dx.doi.org/10.1097/PAI.0b013e318032ea73
33. OH JW, YANG WI, LEE MJ, PARK S, PARK BW et al. The prognostic significance of survivin expression in breast cancer. J Breast Cancer 2009; 12: 285-294. http://dx.doi.org/10.4048/jbc.2009.12.4.285
34. CECKA F, HORNYCHOVA H, MELICHAR B, RYSKA A, JANDIK P et al. Expression of bcl-2 in breast cancer: correlation with clinicopathological characteristics and survival. Acta Medica 2008; 51: 107-112.
35. AL-JOUDI FS, ISKANDAR ZA, HASNAN J, RUSLI J, KAMAL Y et al. Expression of survivin and its clinicopathological correlations in invasive ductal carcinoma of the breast. Singapore Med J 2007; 48: 607-614.
36. SOHN DM, KIM SY, BAEK MJ, LIM CW, LEE MH et al. Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacother 2006; 60: 289-292. http://dx.doi.org/10.1016/j.biopha.2006.06.008
37. RYAN B, O'DONOVAN N, BROWNE B, O'SHEA C, CROWN J et al. Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer. Br J Cancer 2005; 17: 120-124. http://dx.doi.org/10.1038/sj.bjc.6602314
38. SIMPSON JF, GRAY R, DRESSLER LG, COBAU CD, FALKSON CI et al. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 2000; 18: 2059-2069.
39. DRAKE RL, VOGL W, MITCHELL AWM, editors. Grays Anatomy for students. 2nd Edition. Philadelphia: Churchill Livingstone, 2010.
40. LEE JP, CHANG KH, HAN JH, RYU HS Survivin, a novel anti-apoptosis inhibitor, expression in uterine cervical cancer and relationship with prognostic factors. International Journal of Gynecological Cancer 2005; 15: 113-119. http://dx.doi. org/10.1111/j.1048-891X.2005.15011.x
41. MEHROTRA S, LANGUINO LR, RASKETT CHM, MERCURIO AM, DOHI T, ALTIERI DC IAP regulation of metastasis. Cancer Cell 2010; 17: 53-64. http://dx.doi. org/10.1016/j.ccr.2009.11.021
42. ZHANG SQ, QIANG SY, YANG WB, JIANG JT, JI ZZ Expression of survivin in different stages of carcinogenesis and progression of breast cancer. Ai Zheng 2004; 23: 697-700.
43. ALTIERI DC Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-8589. http://dx.doi.org/10.1038/sj.onc.1207113
44. FANGUSARO JR, CALDAS H, JIANG Y, ALTURA RA Survivin: An inhibitor of apoptosis in pediatric cancer. Pediatric Blood & Cancer 2006; 47: 4-13. http://dx.doi.org/10.1002/pbc.20805
45. REXHEPAJ E, JIRSTROM K, O'CONNOR DP, O'BRIEN SL, LANDBERG G et al. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer 2010; 10: 639. http://dx.doi. org/10.1186/1471-2407-10-639
46. BARNES N, HAYWOOD P, FLINT P, KNOX WF, BUNDRED NJ Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. British Journal of Cancer 2006; 94: 253-258. http://dx.doi. org/10.1038/sj.bjc.6602932
47. JIN Q, FENG L, BEHRENS C, BEKELE BN, WISTUBA II, HONG W-K, LEE H-Y Implication of AMP-Activated Protein Kinase and Akt-Regulated Survivin in Lung Cancer Chemopreventive Activities of Deguelin. Cancer Res 2007; 67: 11630-11639. http://dx.doi.org/10.1158/0008-5472.CAN-07-2401